Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Trial Profile

PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole; Paclitaxel; Tamoxifen
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms PAMELA; SOLTI-PAMELA
  • Most Recent Events

    • 17 May 2023 Results (TBCRC023 and PAMELA studies) hypothesizing that a multiparameter classifier can identify patients with HER2 "addicted" tumors who may benefit from a chemotherapy-sparing strategy published in the Clinical Cancer Research
    • 31 May 2020 Results hypothyzing that a multiparameter classifier predicts response to lapatinib plus trastuzumab using baseline specimens from 2 trials (TBCRC023 [NCT00999804] and PAMELA [NCT01973660]) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results of a combined analysis of CALGB40601 (Alliance) and PAMELA clinical trials, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top